{
    "nctId": "NCT05133674",
    "briefTitle": "Therapeutic Dose Monitoring (TDM) of Tamoxifen",
    "officialTitle": "Therapeutic Dose Monitoring (TDM) of Tamoxifen and Its Active Metabolites in Combination With Patient-reported Symptom Scores Among Patients With Breast Cancer Receiving Adjuvant Tamoxifen Treatment",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Breast Carcinoma, Breast Tumors, Cancer of Breast, Malignant Neoplasm of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "To validate the rhelise\u2122 kit for monitoring tamoxifen, 4-hydroxytamoxifen and Z-endoxifen among patients recommended or who have ongoing adjuvant tamoxifen.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged \u2265 18 years with hormone-positive stage 0-3 breast cancer.\n2. Performance status ECOG 0-2.\n3. Ongoing daily adjuvant tamoxifen minimum of 2 months \u00b1 GnRH analogues \u00b1 RT for stage 3 breast cancer.\n4. Locally recurrent disease, previously treated with adjuvant tamoxifen.\n5. Able to use software applications developed specifically for small, wireless computing devices, such as smartphones and tablets.\n6. Have small, wireless computing devices, such as smartphones and tablets.\n\nExclusion Criteria:\n\n1. Fulfilling any of the contraindications for tamoxifen.\n2. Metastatic (stage IV) breast cancer.\n3. Included in other clinical studies receiving not approved investigational medicinal drug.\n4. Ongoing pregnancy or lactation.\n5. Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}